Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme.
Thomas FrisellHannah BowerMatilda MorinEva BaecklundDaniela Di GiuseppeBénédicte DelcoigneNils FelteliusHelena Forsblad-d'EliaElisabet LindqvistUlf LindströmJohan Asklingnull nullPublished in: Annals of the rheumatic diseases (2023)
Data from ARTIS supports that the b/tsDMARDs currently used to treat RA have acceptable and largely similar safety profiles, but differences exist in particular concerning tolerability and specific infection risks.
Keyphrases
- rheumatoid arthritis
- clinical practice
- disease activity
- interstitial lung disease
- rheumatoid arthritis patients
- open label
- cancer therapy
- electronic health record
- study protocol
- human health
- randomized controlled trial
- big data
- systemic lupus erythematosus
- risk assessment
- deep learning
- data analysis
- double blind
- drug delivery